RESEARCH

The potential impact of insulin resistance and metabolic syndrome on migraine headache characteristics

Mona Ali1, Mona Hussein1, Rehab Magdy2, Ahmed Khamis3, Salsabil Abo Al-Azayem2*, Asmaa M Othman4, Aya Ahmed5 and Wesam Osama2

Abstract

Background & objectives: Studying comorbidities with migraine aids in a better understanding of its pathophysiology and potential therapeutic targets. This case-control study aimed to study the impact of insulin resistance and metabolic syndrome on the characteristics of migraine headache attacks.

Methods: A case-control study was conducted on 30 migraine patients and 30 healthy controls. The following data were assessed in migraine patients: type of migraine, duration of attacks, Migraine Severity Scale (MIGSEV), and Headache Impact Test-6 (HIT-6). Both groups were assessed for waist circumference and underwent the following tests: fasting blood glucose, fasting insulin, high-density lipoprotein cholesterol level, and triglycerides, and homeostasis model assessment–insulin resistance (HOMA-IR) was applied.

Results: This study included age and sex-matched patients and controls. Migraine patients had significantly higher waist circumference, higher mean values of serum insulin, HOMA-IR and higher frequency of insulin resistance and metabolic syndrome than the control group (P-value = 0.005, 0.049, 0.01, 0.012, 0.024, respectively). Migraine patients with insulin resistance had significantly higher intensity and tolerability scores, MIGSEV total score, and HIT-6 total score compared to those without (P-value = 0.005, 0.005, 0.002, 0.018, respectively). There was a significantly positive correlation between the MIGSEV and HIT-6 scores and fasting insulin levels, and HOMA-IR value (P-value = 0.006, ≤ 0.001, 0.017, ≤ 0.001, respectively).

Conclusion: Insulin resistance and metabolic syndrome are more common in migraine patients than in healthy controls. The severity and impact of migraine attacks are higher in patients with insulin resistance than those without.

Keywords: Migraine, Insulin resistance, Metabolic syndrome, MIGSEV, Headache impact Test-6

Introduction

In 2019, by the Global Burden of Disease (GBD) study, migraine was declared the second cause of disability and the first among young females [1]. Studying the comorbid conditions commonly encountered with migraine and their effect on migraine severity aids in a better understanding of the pathophysiology of migraine and the potential therapeutic targets [2].

Insulin resistance (IR) is defined as an impaired response of target cells to insulin. Different mechanisms could be related to Insulin sensitivity, including insulin receptors downregulation, the inability of insulin receptors to bind to insulin, or abnormal insulin signalling cascade activation [3]. Insulin resistance causes impairment of glucose metabolism leading to a compensatory increase in insulin production and hyperinsulinemia.
By time, insulin resistance can lead to metabolic syndrome [4]. There is increasing evidence that insulin resistance underlies the pathogenesis of abdominal obesity, diabetes, and hypertension, which are components of metabolic syndrome.

Some studies have shown that insulin resistance is related to migraine [5, 6]. Yet such an association was not ascertained by S Sacco et al. [7] and RK Özcan and SG Özmen [8]. The components of metabolic syndrome, such as hypertension, diabetes, and obesity, were also common in patients with migraine [5, 8, 9]. Epidemiological data estimated a 1-year prevalence of migraine in metabolic syndrome to be 11.9% in men and 22.5% in women [10]. However, the exact relationship is still unclear, and their relation to migraine characteristics is still not well established [11].

Accordingly, this case-control study aimed to study the impact of insulin resistance and metabolic syndrome on the characteristics of migraine headache attacks.

Methods

Study population

The present case-control study was conducted on 30 newly diagnosed migraine patients fulfilling ICHD-3 criteria for migraine [12] and aged 18–50 years. The patients were consecutively recruited from Beni Suef University Hospital Neurology clinic from June 1, 2021, to September 1, 2021. Another 30 age and sex-matched healthy relatives of those patients were enrolled as controls during the same period to ensure the nearly same socioeconomical level and nutritional habits between patients and the control groups.

Exclusion criteria included endocrine diseases, such as diabetes mellitus or thyroid dysfunction, and drugs with known effects on the lipid profile, insulin levels, or body weight, such as statins, fibrates, valproate, steroids, oral contraceptive pills, etc. Pregnant women were also excluded from the study.

Procedures

Demographic data were collected from both patients and control groups. Waist circumference was also measured for patients and controls using a plastic tape measure midway between the last rib and the iliac crest at the end of normal expiration. Migraine patients were evaluated regarding the type of migraine (with or without aura), duration of untreated headache attacks, presence or absence of allodynia, and autonomic manifestations. The migraine severity was assessed based on patient self-report by the Migraine Severity Scale (MIGSEV) [13], which relies on four items: intensity of pain, disability in daily activity, tolerability, and nausea. The Headache Impact Test-6 (HIT-6) [14] was used to estimate the burden of headache, entailing six items: pain, social functioning, role functioning, vitality, cognitive functioning, and psychological distress.

Both patients and control groups underwent the following laboratory tests: fasting blood glucose (FBG), fasting insulin, high-density lipoprotein cholesterol level (HDL), and triglycerides (TGs).

Blood samples were collected by antecubital venipuncture in vacutainer tubes with Na Fluoride as an anticoagulant for blood glucose and without anticoagulant for the rest of the results after fasting.

Routine chemistry investigations, including HDL-C, TG, and FBG, were analyzed on an automated Benchtop chemistry analyzer Flexor. Commercial kits were supplied by ELI Tech; ELI Tech: SEPPIM S.A.S – Zone Industrielle – 61,500 SEES FRANCE. Measuring fasting insulin level by enzyme-linked immunosorbent assay (ELISA): The kit uses a double-antibody sandwich ELISA technique.

The homeostasis model assessment–insulin resistance (HOMA-IR) was applied as follows: fasting insulin (µU/mL) × fasting glucose (mmol/L) /22.5 [15]. If the HOMA-IR value >2.5 indicates a state of insulin resistance [16].

The National Cholesterol Education Program Adult Treatment Panel III (ATP III) criteria [17] necessitate at least three of the following to define metabolic syndrome: FBG ≥ 100 mg/dL, blood pressure ≥ 130/80 mmHg, a waist circumference of > 90 cm for men and > 80 cm for women, HDL cholesterol of < 40 mg/dL for men and < 50 mg/dL for women, and TGs > 150 mg/dL.

Sample size

Before starting the study, the sample size was calculated using G*Power version 3.1.9.7 Software. The effect size was calculated based on the mean values of HOMA in migraine patients and controls in a study conducted by Fava et al. [5]. The statistical test used was the independent sample t-test. The type of power analysis was: A priori: compute required sample size- given α, power, and effect size. The input parameters were: tail(s) = two, effect size d = 1.37, α err prob = 0.05, power (1-β err prob) = 0.95, and allocation ratio N2/N1 = 1. The output parameters were: non centrality parameter δ = 3.753, critical t = 2.048, and Df = 28. A total sample size of 30 patients in both patients and control groups was required to achieve a statistical power (1–β) of 95%.

Statistical analysis

IBM SPSS (Statistical Package of Social Science) Version 25 was used to analyze the data. Kolmogorov–Smirnov test was used to test the normality of data. Non-normally distributed quantitative variables were expressed
as the median and interquartile range (IQR), while normally distributed quantitative variables were expressed as mean and standard deviation. Categorical variables were expressed as numbers and percentages. An independent sample t-test was used to compare migraine patients and the control group in quantitatively normally distributed variables. In contrast, the Mann-Whitney test was used to compare the two groups in quantitative, non-normally distributed variables. Chi-squared test was used to compare migraine patients and the control group in categorical variables. Correlations between the duration and severity of migraine attacks and the laboratory markers of insulin resistance and metabolic syndrome were done using the Spearman correlation test. Multivariate regression analysis was done to detect the laboratory markers associated with increased duration and severity of migraine headache attacks. The independent variables were FBS, TGs, HDL, Insulin, and HOMA-IR. P-value ≤ 0.05 was considered statistically significant. All tests were two-tailed.

**Results**

**Demographics, clinical and laboratory characteristics of migraine patients and controls**

This case-control study was conducted on 30 migraine patients and 30 age and sex-matched controls (P-value = 0.734, 0.766, respectively). There was a statistically significant difference between migraine patients and controls regarding the mean value of waist circumference [92.43 ± 11.14 cm vs. 84.9 ± 8.42 cm, P-value = 0.005]). Only five migraine patients (16.7%) were known to be hypertensive.

Migraine patients had significantly higher mean values of serum insulin and HOMA-IR than the control group (P-value = 0.049, 0.01, respectively). Whereas, there were no statistically significant differences between migraine patients and controls regarding FBS, TGs, or HDL (P-value = 0.719, 0.282, 0.397, respectively).

Migraine patients had a significantly higher frequency of insulin resistance (46.7%) in comparison to controls (16.7%) (P-value = 0.012). Also, the frequency of metabolic syndrome was significantly higher in migraine patients (43.3%) in comparison to controls (16.7%) (P-value = 0.024) (Table 1).

**Characteristics of migraine headache attacks in the included migraine patients**

The median value for the duration of untreated migraine headache attacks was 12 h with IQR (8–13.75). Only 23.3% of migraine patients had an aura, 6.7% had autonomic manifestations, and 30% had allodynia. The median value for MIGSEV total score was 2 with IQR (1–3), while the median value for the HIT-6 total score was 59 with IQR (49–64) (Table 2).

**The impact of insulin resistance and metabolic syndrome on the characteristics of migraine headache attacks**

Migraine patients with insulin resistance had significantly higher intensity and tolerability scores, MIGSEV total score, and HIT-6 total score compared to those without insulin resistance (P-value = 0.005, 0.005, 0.002, 0.018, respectively). Whereas, there were no statistically significant differences between migraine patients with and without insulin resistance regarding the duration of untreated migraine headache attacks, aura, autonomic manifestations, allodynia, disability score, or nausea (Table 2).

There were no statistically significant differences between migraine patients with and without metabolic syndrome regarding the duration of untreated migraine headache attacks, aura, autonomic manifestations, allodynia, intensity, disability or tolerability scores, nausea, MIGSEV total score, or HIT-6 total score (Table 3).

There was a statistically significant negative correlation between the duration of untreated migraine headache attacks and HDL (P-value = 0.002). There were statistically significant positive correlations between MIGSEV total score and FBS, insulin, and HOMA-IR serum levels (P-value = 0.016, 0.006, ≤ 0.001 respectively), and also between HIT-6 total score, and both insulin and HOMA-IR serum levels (P-value = 0.017, ≤ 0.001 respectively) (Table 4).

Multivariate regression analysis was done to detect the laboratory markers associated with increased duration and severity of migraine headache attacks. The independent variables were FBS, TGs, HDL, Insulin, and HOMA-IR.

HDL was found to be associated with increased duration of migraine headache attacks (P-value = 0.039), whereas HOMA-IR was associated with increased MIGSEV and HIT-6 total scores (P-value ≤ 0.001, 0.002, respectively) (Table 5).

**Discussion**

The impairment of glucose metabolism in migraine is an imperative topic of interest. Recently, EC Gross et al. [18] described migraine as an adaptive response in genetically predisposed individuals with unbalanced cerebral energy metabolism.

The current study confirmed the presence of a significant relationship between migraine and insulin resistance; the migraine group had a significantly higher frequency of insulin resistance than normal controls. Similarly, HOMA-IR was employed to measure insulin resistance in the migraine research field by SK Bhoi et al. [9], A Fava et al.
Nevertheless, only two former studies found an association between migraine and insulin resistance. On the other hand, other studies have obtained similar results using different assessment methods of insulin resistance other than the HOMA-1R technique [6, 19].

### Table 1
Demographics, clinical and laboratory characteristics of migraine patients and controls

|                      | Migraine patients (n = 30) | Controls (n = 30) | P-value |
|----------------------|-----------------------------|-------------------|---------|
| Age in years [median (IQR)] | 34.5 (27–43) | 36.5 (26–41) | 0.734^1 |
| Sex [n (%)]          | Males 8 (26.7%) | 7 (23.3%) | 0.766^2 |
|                      | Females 22 (73.3%) | 23 (76.7%) |
| Waist circumference in cm [mean (SD)] | 92.43 (11.14) | 84.9 (8.42) | 0.005^3 |
| HTN [n (%)]          | 5 (16.7%) |          |
| Attack duration in hours [median (IQR)] | 12 (8–13.75) |          |
| Aura [n (%)]         | 7 (23.3%) |          |
| Autonomic manifestations [n (%)] | 2 (6.7%) |          |
| Allodynia [n (%)]    | 9 (30%) |          |
| MIGSEV Scale [median (IQR)] | 3 (2–3) | 3 (2–3) |         |
|                      | Intensity 2 (1–2) |          |
|                      | Disability 2 (1–3) |          |
|                      | Nausea 1 (1–2) |          |
| HIT-6 total score [median (IQR)] | 59 (49–64) |          |
| Laboratory work up [mean (SD)] | 87.87 (12.19) | 86.8 (10.6) | 0.719^3 |
| FBS                  | 97.4 (49.45) | 109.77 (37.97) | 0.282^3 |
| TGs                  | 50.51 (11.25) | 52.93 (10.76) | 0.397^3 |
| HDL                  | 7.03 (2.997) | 5.37 (3.41) | 0.049^3 |
| Insulin              | 1.72 (0.79) | 1.17 (0.81) | 0.01*^3 |
| HOMA-IR              | 14 (46.7%) | 5 (16.7%) | 0.012^2 |
| Insulin resistance [n (%)] | 13 (43.3%) | 5 (16.7%) | 0.024^2 |
| Metabolic syndrome [n (%)] | 13 (43.3%) | 5 (16.7%) | 0.024^2 |

**Note:** FBS Fasting blood sugar, HDL High-density lipoprotein, HIT-6 Headache Impact Test-6, HOMA-IR Homeostatic Model Assessment for Insulin Resistance, HTN Hypertension, MIGSEV Migraine Severity Scale, TGs Triglycerides

1 Mann-Whitney test, 2Chi-squared test, 3Independent sample t-test

*P-value ≤ 0.05 is considered significant

### Table 2
Characteristics of migraine in patients with and without insulin resistance

|                      | Migraine patients with insulin resistance (n = 14) | Migraine patients without insulin resistance (n = 16) | P-value |
|----------------------|---------------------------------------------------|-----------------------------------------------------|---------|
| Attack duration in hours [median (IQR)] | 12 (11–14) | 9 (6.5–15) | 0.22^1 |
| Aura [n (%)]         | 3 (21.4%) | 4 (25%) | 0.818^2 |
| Autonomic manifestations [n (%)] | 1 (7.1%) | 1 (6.3%) | 0.922^2 |
| Allodynia [n (%)]    | 4 (28.6%) | 5 (31.3%) | 0.873^2 |
| MIGSEV Scale [median (IQR)] | 3 (3–4) | 2 (2–3) | 0.005^*1 |
|                      | Intensity 2 (2–3) |          |
|                      | Disability 2.5 (2–4) |          |
|                      | Tolerability 2 (1–2) |          |
|                      | Nausea 2 (1–3) |          |
| Total score          | 3 (2–3) | 1.5 (1–2.75) | 0.002^*1 |
| HIT-6 total score [median (IQR)] | 63 (58.25–64.25) | 55.5 (42–61.25) | 0.018^*1 |

**Note:** HIT Headache Impact Test-6, MIGSEV Migraine Severity Scale

1 Mann-Whitney test, 2Chi-squared test

*P-value ≤ 0.05 is considered significant

[5], S Sacco et al. [7], and RK Özcan and SG Özmen [8]. Nevertheless, only two former studies found an association between migraine and insulin resistance. On the other hand, other studies have obtained similar results using different assessment methods of insulin resistance other than the HOMA-1R technique [6, 19].
Concerning these previously published reports, the impact of insulin resistance on the severity and duration of headache attacks was only studied by SK Bhoi et al. [9]. Contrary to our findings, SK Bhoi et al. [9] found that the duration of attacks was significantly longer in migraine patients with insulin resistance than in those without insulin resistance, but no significant difference regards headache severity. At the same time, the current study showed a significantly positive correlation between the MIGSEV and HIT-6 scores and fasting insulin levels, and HOMA-IR value.

At the brain level, insulin resistance is proposed to lead to impaired neurotransmitter release, altered neuronal and glial cell receptor regulation, or homeostatic and inflammatory responses to insulin. All these mechanisms are proposed to be hypothetical models for the relation of insulin resistance and metabolic syndrome to migraine [11, 20].

### Table 3  Characteristics of migraine in patients with and without metabolic syndrome

| Characteristic                        | Migraine patients with metabolic syndrome (n = 13) | Migraine patients without metabolic syndrome (n = 17) | P-value |
|---------------------------------------|--------------------------------------------------|-----------------------------------------------------|---------|
| Attack duration in hours [median (IQR)]| 12 (8–17.5)                                     | 12 (7.5–12)                                        | 0.259   |
| Aura [n (%)]                          | 2 (15.4%)                                        | 5 (29.4%)                                          | 0.368   |
| Autonomic manifestations [n (%)]      | 1 (7.7%)                                         | 1 (5.9%)                                           | 0.844   |
| Allodynia [n (%)]                     | 5 (38.5%)                                        | 4 (23.5%)                                          | 0.367   |
| MIGSEV Scale [median (IQR)]           |                                                  |                                                    |         |
| Intensity                             | 3 (2–3.5)                                        | 3 (2–3)                                            | 0.807   |
| Disability                            | 3 (2–3)                                          | 3 (2–3)                                            | 0.657   |
| Tolerability                          | 2 (1.5–2.5)                                      | 2 (1–2.5)                                          | 0.82    |
| Nausea                                | 2 (1.5–4)                                        | 2 (1–3)                                            | 0.529   |
| Total score                           | 3 (1.5–3)                                        | 2 (1–3)                                            | 0.26    |
| HIT-6 total score [median (IQR)]      | 63 (48–64)                                       | 59 (47–62.5)                                       | 0.628   |

HIT: Headache Impact Test-6, MIGSEV: Migraine Severity Scale

1 Mann-Whitney test, 2 Chi-squared test

P-value > 0.05 is considered non-significant

### Table 4  Correlations between duration and severity of migraine attacks and the laboratory markers of insulin resistance and metabolic syndrome

| Attack duration | MEGSEV | HIT | FBS | TGs | HDL | Insulin | HOMA-IR |
|-----------------|--------|-----|-----|-----|-----|---------|---------|
| Attack duration | (r) Coef. | 1   | 0.333 | 0.366 | 0.148 | 0.077 | -0.534 | 0.134 | 0.299 |
|                 | P-value | .   | 0.072 | 0.047* | 0.434 | 0.686 | 0.002* | 0.482 | 0.108 |
| MEGSEV           | (r) Coef. | .   | 0.333 | 1    | 0.705 | 0.437 | 0.302 | -0.164 | 0.486 | 0.721 |
|                 | P-value | .   | 0.072 | <0.001* | 0.016* | 0.104 | 0.387 | 0.006* | <0.001* |
| HIT              | (r) Coef. | .   | 0.366 | 0.705 | 1    | 0.325 | 0.295 | -0.026 | 0.433 | 0.704 |
|                 | P-value | .   | 0.047* | <0.001* | . | 0.08 | 0.114 | 0.891 | 0.017* | <0.001* |
| FBS              | (r) Coef. | .   | 0.148 | 0.437 | 0.325 | 1    | 0.521 | -0.282 | 0.358 | 0.390 |
|                 | P-value | .   | 0.434 | 0.016* | 0.08 | . | 0.003* | 0.131 | 0.052 | 0.033* |
| TGs              | (r) Coef. | .   | 0.077 | 0.302 | 0.295 | 0.521 | 1    | -0.213 | 0.268 | 0.317 |
|                 | P-value | .   | 0.686 | 0.104 | 0.114 | 0.003* | . | 0.258 | 0.152 | 0.088 |
| HDL              | (r) Coef. | .   | -0.534 | -0.164 | -0.026 | -0.282 | -0.213 | 1    | 0.111 | 0.071 |
|                 | P-value | .   | 0.002* | 0.387 | 0.891 | 0.131 | 0.258 | . | 0.559 | 0.708 |
| Insulin          | (r) Coef. | .   | 0.134 | 0.486 | 0.433 | 0.358 | 0.268 | 0.111 | 1    | 0.813 |
|                 | P-value | .   | 0.482 | 0.006* | 0.017* | 0.052 | 0.152 | 0.559 | . | <0.001* |
| HOMA-IR          | (r) Coef. | .   | 0.299 | 0.721 | 0.704 | 0.390 | 0.317 | 0.071 | 0.813 | 1    |
|                 | P-value | .   | 0.108 | <0.001* | <0.001* | 0.033* | 0.088 | 0.708 | <0.001* | . |

FBS: Fasting blood sugar, HDL: High-density lipoprotein, HIT: Headache Impact Test-6, HOMA-IR: Homeostatic Model Assessment for Insulin Resistance, MIGSEV: Migraine Severity Scale, TGs: Triglycerides

(r): Spearman coefficient, *P-value ≤ 0.05 is considered significant
In light of these observations, B Guldiken et al. [10] endorsed careful assessment for impaired glucose metabolism in patients with migraine. Various methods have emerged to correct insulin resistance or hyperinsulinism, such as insulin-sensitizing drugs, physical activity, and dietary interventions [21, 22]. Ultimately, these therapeutic modalities are worthy of being evaluated from this perspective to assess their effects on migraine.

In agreement with previous studies [9, 10], this study showed a statistically significant higher frequency of metabolic syndrome in the migraine group than in normal controls. Yet, no significant effect of metabolic syndrome was detected on the severity or duration of migraine attacks. In contrast, SK Bhoi et al. [9] found that the duration of attacks was significantly longer in migraine patients with metabolic syndrome than in those without, but no significant difference regards headache severity.

Regarding different components of metabolic syndrome, this study showed a significantly higher waist circumference in migraine patients than in normal controls. The relation between migraine and abdominal obesity was also stated in previous reports [23, 24]. Adipose tissue is largely accepted as an endocrine gland from which many pro-inflammatory cytokines can be produced, including IL-6 and TNF-α [24]. Their levels increase just before initiating a migraine attack [25].

The association between dyslipidemia and migraine is controversial. Some studies have shown a higher frequency of dyslipidemia in migraine than in healthy controls [19, 26], while others did not find such a relationship [8, 9]. Although this study did not find a statistically significant difference between migraine and normal controls regarding TGs and HDL levels, a negative correlation was observed between decreased HDL levels and increased headache duration. Z Bic et al. [27] proposed that elevated blood lipids might lead to increased platelet aggregation, decreased serotonin levels, and elevated prostaglandin levels, causing vasodilatation that heralds a migraine attack.

This study had some limitations. First, a small sample size hindered further comparative analysis between migraine subgroups (migraine with aura vs. migraine without aura). Second, its cross-sectional design in which the exact sequence of the medical events could not be recognized.
Conclusion

Insulin resistance and metabolic syndrome are more common in migraine patients than in healthy controls. The severity and impact of migraine headache attacks are higher in patients with insulin resistance than in those without insulin resistance. At the same time, they are not different in patients with and without metabolic syndrome. The higher the HOMA-IR value level, the more severe the migraine headache attacks.

Acknowledgements

Not applicable.

Authors’ contributions

MA participated in the study design and collection of data. MH participated in the study design, analysis and interpretation of data and helped to draft the manuscript. RM participated in the interpretation of data and helped to draft the manuscript. AK participated in the study design and collection of data. SA participated in the collection of data and helped to draft the manuscript. AO participated in doing the laboratory workup and helped to draft the manuscript. WO participated in the interpretation of data and helped to draft the manuscript. All authors read and approved the final manuscript.

Funding

Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). The authors did not receive any funding for this work.

Availability of data and materials

Authors report that the datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate

Written informed written consent was signed by all the patients and controls. The study was performed in agreement with the Declaration of Helsinki. Ethical approval for this study was obtained from the Research ethical committee of Beni-Suef University.

Consent for publication

Not applicable.

Competing interests

Authors have no competing interests.

Author details

1 Department of Neurology, Beni-Suef University, Beni-Suef, Egypt. 2 Department of Neurology, Cairo University, Cairo, Egypt. 3 Beni-Suef General Hospital, Beni-Suef, Egypt. 4 Department of Internal Medicine, Beni-suef University, Beni- Suef, Egypt. 5 Department of Clinical and Chemical Pathology, Beni-suef University, Beni-Suef, Egypt.

Received: 14 August 2022   Accepted: 4 November 2022   Published online: 12 November 2022

References

1. Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z, on behalf of Lifting The Burden: the Global Campaign against H. Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21(1):137. https://doi.org/10.1186/s10194-020-10194-0.
2. Buse DC, Reed ML, Fanning KM, Bostic R, Dodick DW, Schwedt TJ, et al. Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study. J Headache Pain. 2020;21(1):23. https://doi.org/10.1186/s10194-020-1084-y.
3. Petersen MC, Shulman GI. Mechanisms of Insulin Action and Insulin Resistance. Physiol Rev. 2018;98(4):2133–223. https://doi.org/10.1152/physrev.00063.2017.
4. Wilcox G. Insulin and insulin resistance. Clin Biochem Rev. 2005;26(2):19–39.
5. Fava A, Pirritano D, Consoli D, Plastino M, Casaliniuovo F, Cristofaro S, et al. Chronic migraine in women is associated with insulin resistance: a cross-sectional study. Eur J Neurol. 2014;21(2):267–72. https://doi.org/10.1111/ene.12289.
6. Rainero I, Limone P, Ferrero M, Valfre W, Pelissetto C, Rubino E, et al. Insulin sensitivity is impaired in patients with migraine. Cephalalgia. 2005;25(8):593–7. https://doi.org/10.1111/j.1468-2982.2005.00928.x.
7. Sacco S, Alotelli E, Omello R, Ripa P, Pistola F, Carolei A. Insulin resistance in migraineurs: results from a case-control study. Cephalalgia. 2014;34(5):349–56. https://doi.org/10.1177/0333102413511155.
8. Özcan RK, Ozmen SG. The Association Between Migraine, Metabolic Syndrome, Insulin Resistance, and Obesity in Women: A Case-Control Study. Sisli Etfal Hastan Tip Bul. 2019;53(3):394–402. https://doi.org/10.15744/SEMB.2018.09982.
9. Bhoi SK, Kalita J, Misra UK. Metabolic syndrome and insulin resistance in migraine. J Headache Pain. 2012;13(4):321–6. https://doi.org/10.1186/s10194-012-0146-y.
10. Guldiken B, Guldiken S, Taskiran B, Koc G, Turgut N, Kabayel L, et al. Migraine in metabolic syndrome. Neurologist. 2009;15(2):55–8. https://doi.org/10.1097/NRL.0b013e31817781bb.
11. Del Moro L, Rota E, Pirovano E, Rainero I, Migraine. Brain glucose metabolism and the “Neuroenergetic” hypothesis: a scoping review. J Pain. 2022. https://doi.org/10.1007/jp pain.2022.02.006.
12. The International Classification of Headache Disorders. 3rd edition (beta version). Cephalalgia. 2013;33(9):629–808. https://doi.org/10.1177/0333102413485658.
13. El Hasnaoui A, Vray M, Richard A, Nachit-Quinekh F, Bourreau F. Assessing the severity of migraine: development of the MISGEV scale. Headache. 2003;43(6):628–35. https://doi.org/10.1046/j.1526-4610.2003.03105.x.
14. Kosinski M, Baylis MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A, et al. A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res. 2003;12(8):963–74. https://doi.org/10.1023/A:102919311193.
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9. https://doi.org/10.1007/bf00280883.
16. Owei I, Umekwe N, Provo C, Wan J, Dagogo-Jack S. Insulin-sensitive and insulin-resistant obese and non-obese phenotypes: role in prediction of incident pre-diabetes in a longitudinal biracial cohort. BMJ Open Diabetes Res Care. 2017;51:e000415. https://doi.org/10.1136/bmjdr-c-2017-000415.
17. Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):4143–421.
18. Gross EC, Lisicki D, Fischer D, Sándor PS, Schoenen J. The metabolic face of migraine — from pathophysiology to treatment. Nat Reviews Neurol. 2019;15(11):627–43. https://doi.org/10.1038/s41582-019-0255-4.
19. Cavestro C, Rosatello A, Micca G, Ravottolo M, Marino M, Asteiggiano G, et al. Insulin metabolism is altered in migraineurs: a new pathogenic mechanism for migraine? Headache. 2007;47:1436–42. https://doi.org/10.1111/j.1526-4610.2007.00719.x.
20. Del Moro L, Rota E, Pirovano E, Rainero I, Migraine. Brain glucose metabolism and the “Neuroenergetic” hypothesis: a scoping review. J Pain. 2022. https://doi.org/10.1007/jp pain.2022.02.006.
21. Mastrottotaro L, Roden M. Insulin resistance and insulin sensitizing agents. Metab Clin Exp. 2021;125:154892. https://doi.org/10.1016/j.metabol.2021.154892.
22. Hassan SA, Farouque U, Choudhry AS, Pillai B, Sheikh FN. Therapeutic implications of altered energy metabolism in migraine: a state-of-the-art review. Curesus. 2020;12(6):e8571-e. https://doi.org/10.7759/curesus.8571.
23. Ojha P, Malhotra V, Pandey N, Singh S. Effect of abdominal obesity on migraine features in Indian population. Natl J Physiol Pharm Pharmacol. 2018;1; https://doi.org/10.5455/njppp.2018.8.0205913022018.

24. Kristoffersen ES, Barte S, Hagen K, Zwart JA, Winsvold BS. Migraine, obesity and body fat distribution - a population-based study. J Headache Pain. 2020;21(1):97. https://doi.org/10.1186/s10194-020-01163-w.

25. Kursun O, Yemisci M, van den Maagdenberg AMJM, Karatas H. Migraine and neuroinflammation: the inflammasome perspective. J Headache Pain. 2021;22(1):55. https://doi.org/10.1186/s10194-021-01271-1.

26. Assarzadegan F, Hosseimpanahi SP, Hesami O, Mansouri B, Lima BS. Frequency of dyslipidemia in migraineurs in comparison to control group. J Family Med Prim Care. 2019;8(3):950–4. https://doi.org/10.4103/jfmpc.jfmpc_9_19.

27. Bic Z, Blix GG, Hopp HP, Leslie FM. In search of the ideal treatment for migraine headache. Med Hypotheses. 1998,50(1):1–7. https://doi.org/10.1016/s0306-9877(98)90170-0.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions